Search is Powered by Google
Breast Cancer News

GSK Breast Cancer Drug Tykerb Referred To European Advisory Committee For Review Following Release Of Data

Main Category: Breast Cancer
Also Included In: Regulatory Affairs / Drug Approvals
Article Date: 21 Mar 2008 - 9:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:3 stars

3 (2 votes)

Health Professional:4 and a half stars

4.5 (2 votes)

Article Opinions: 0 posts

GlaxoSmithKline on Tuesday announced that the European Commission has referred its breast cancer drug Tyverb, sold in the U.S. as Tykerb, to the European Union's Committee for Medicinal Products for Human Use after new data found a risk of elevated liver enzymes in women taking the drug, Reuters Health reports. Tykerb is taken in combination with Roche's breast cancer treatment Xeloda to treat women with HER2-positive breast cancer, an aggressive form of the disease found in about 25% of breast cancer patients that involves extra copies of the HER2 protein.

CHMP in December 2007 conditionally approved the drug but said additional data was necessary (Reuters Health, 3/18). Final CHMP approval had been expected by March 8 (Berton, Dow Jones, 3/18). A review of clinical trials and postmarketing data found that hepatotoxicity, or elevated liver enzyme, was present in four of every 1,000 women who took the drug, according to GSK. The company in a statement said the side effect was "uncommon" and that the liver enzymes "generally returned to normal" after treatment.

According to Mike Ward, an analyst at Nomura Code, the new data likely will not change the risk-benefit profile of the drug. He said that it could add a "slight delay" to the drug's "official approval." Ward said the risk of elevated liver enzymes will be added to the drug's label but will not be a "major issue" (Reuters Health, 3/18).

GSK provided information about the new data to scientists overseeing clinical trials and health care providers in countries where the drug is approved. The company also sent a letter to physicians advising them to monitor the liver enzymes of patients taking the drug. A company spokesperson did not speculate on whether FDA will take any action as a result of the new data. FDA officials were unavailable for comment.

CHMP likely will discuss the drug at its next regulatory meeting, which is scheduled for April 21 to April 24, Dow Jones reports (Dow Jones, 3/18).

Reprinted with kind permission from http://www.nationalpartnership.org. You can view the entire Daily Women's Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women's Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company.

© 2007 The Advisory Board Company. All rights reserved.

View drug information on Tykerb; Xeloda.





Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Breast Cancer Cardiovascular GI Prostate Cancer Psychiatry Respiratory Learning Resources Migraine Urology
Asthma Bipolar Blood Pressure Breast Cancer (Patient) Heartburn

Sign up to receive newsletters / news alerts
MedReader RSS Reader




Breast Cancer Clinical Trials image Breast Cancer Clinical Trials

There are now a wide variety of treatment options for breast cancer. How do you make sense of them all? Learn what experts have to say about the newest research and how it can affect you...

Breast Cancer Recurrence image Breast Cancer Recurrence

Women and their doctors sometimes have different perspectives on the treatment for breast cancer. Listen to experts discuss treatment goals and the impact these have on daily life...

View more videos...

Add Your Advertisement Here